Tweets
Interim analysis of AURORA 2 Extension study:
🦋Voclosporin maintained meaningful reductions in UPCR and eGFR remained stable until month 30.
🦋No unexpected new AEs
Promising results!
@RheumNow #ACR21 #ACRBest abs1425 https://t.co/hBB6k0bDYb
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)
Dr. Sheila Reyes, ( @RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21.
https://t.co/Q50kEr5WEU https://t.co/5DScK5krtw
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 8 months ago
AxSpA: Geographic Prevalence Association with HLA-B27: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate discusses abstract #0368 presented at the #ACR21 annual meeting.
https://t.co/CnIjlWuKjZ https://t.co/vytIdK9CCo
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
#ACR21 #Abstr1457 Nine more well-phenotyped patients with VEXAS were presented. New info:
💠Peritubular capillaritis & cryo vasculitis
💠Most cs- & bDMARDs had limited efficacy
💠Potential therapy with plasma cell blockade & stem cell transplant
@RheumNow https://t.co/iDwJAdbf4M https://t.co/X4ENz4M91u
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
4 years 8 months ago
This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24.
Reassuring data.
@RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Interesting results where cannabidiol NEG results in RCT in hand OA and PsA. ? Throw out the ‘pot’with the dish water? Did it stimulate appetites? Was pain the same but interference less? Abst#1456 #ACR21 @RheumNow https://t.co/rnz82Paxkr
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
Interesting question came up: why would you change a RA patient from JAKi to JAKi?
The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way).
That would clearly favour to better survival
#ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
#ACR21 #Abstr1484 Hands down one of the most impressive results and trial design. RHAPSODY: Rilonacept led to ⬇️risk of pericarditis recurrence vs PBO (7% vs 74%; HR 0.04). Median time to resolution of pain and CRP were 5 & 7 Days. FDA approved @RheumNow https://t.co/Zty2WnkJEQ https://t.co/xGqt9Lwvjj
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
4 years 8 months ago
RheumNow’s expanded coverage of the #ACR21 meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Realised i have not been out of house apart from hospital visits 😳🙈#MeTime outdoor in the UK 🇬🇧 Falls season while enjoying #ACR21 talks by the New Masters @RheumNow #Rheumpix https://t.co/HYLKkECvCv
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
4 years 8 months ago
